Core Insights - Mirum Pharmaceuticals (MIRM) reported a loss of 11 cents per share in Q4 2025, missing the Zacks Consensus Estimate of earnings of 2 cents, but improved from a loss of 49 cents per share in the same quarter last year [1][10] - Revenues for Q4 totaled $148.9 million, representing a 50.5% year-over-year increase, surpassing the Zacks Consensus Estimate of $141 million, driven by strong sales of Livmarli and newly acquired bile acid medicines [2][8] Financial Performance - The company recorded no license and other revenues in the year-ago quarter, while research and development expenses rose by 16.1% year-over-year to $51.1 million [6] - Selling, general and administrative expenses increased by 30.5% to $74.1 million compared to the previous year [9] - For the full year 2025, Mirum generated revenues of $521.3 million, up from $336.9 million in 2024, with a loss of 47 cents per share, an improvement from a loss of $1.85 in the prior year [10] Product and Pipeline Updates - Livmarli is approved for treating cholestatic pruritus in patients with Alagille syndrome and certain patients with progressive familial intrahepatic cholestasis [3] - A new tablet formulation of Livmarli was launched in the U.S. in June 2025, aimed at providing convenience for older patients [4] - Mirum acquired Travere Therapeutics' bile acid products in August 2023, adding Cholbam and Ctexli to its portfolio [4] - The company expects worldwide net product sales of approximately $630-$650 million in 2026 and aims to achieve positive cash flow in 2027 [11] Clinical Trials and Research - Mirum is conducting a phase III EXPAND study for Livmarli to treat pruritus in rare cholestatic conditions, with enrollment expected to complete in the first half of 2026 [12] - The lead pipeline candidate, volixibat, is being evaluated in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis, with top-line data expected in 2026 [13] - The company initiated the phase II BLOOM study for MRM-3379, a PDE4D inhibitor for Fragile X syndrome, and completed the acquisition of Bluejay Therapeutics, adding brelovitug to its pipeline [14] Stock Performance - Mirum's shares have increased by 45.5% over the past six months, outperforming the industry average rise of 23% [5]

Core Insights - Mirum Pharmaceuticals reported a narrower loss of $0.12 per share for Q2 2025, compared to a loss of $0.52 per share in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of $0.31 per share [1][8] - Revenues for Q2 2025 reached $127.8 million, reflecting a year-over-year increase of 64.1%, surpassing the Zacks Consensus Estimate of $108 million, driven by strong sales of Livmarli and newly acquired bile acid products [2][8] - The company raised its revenue guidance for 2025 to a range of $490 million to $510 million, up from the previous estimate of $435 million to $450 million, due to the strong performance of Livmarli [10] Financial Performance - Livmarli's net product sales were $88.2 million in Q2 2025, marking an 87% increase year-over-year, with U.S. sales at $57 million and ex-U.S. sales at $31.2 million [7][8] - Net product sales from bile acid products, including Cholbam and Ctexli, totaled $39.6 million in Q2 2025, reflecting a 30% year-over-year increase [7] - Research and development expenses rose by nearly 41% year-over-year to $46.1 million, while selling, general, and administrative expenses increased by approximately 28.7% to $63.3 million [9] Recent Developments - Mirum is conducting a phase III EXPAND study for Livmarli to treat pruritus in rare cholestatic conditions, with enrollment expected to complete in 2026 [11] - The FDA approved a new tablet formulation of Livmarli, launched in the U.S. in June 2025, aimed at improving convenience for older patients [11] - The lead pipeline candidate, volixibat, is under evaluation in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis, with top-line data expected in Q2 2026 [12] Stock Performance - Mirum's shares increased by 8.6% in after-hours trading on August 6, 2025, following the better-than-expected results and raised revenue guidance [4] - Year-to-date, Mirum's stock has risen by 29.1%, significantly outperforming the industry average increase of 0.2% [6]